ORKA
NASDAQOruka Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
Price$101.87+43.19 (+73.60%)
2026-05-212026-08-25
News · 26 weeks64+450%
2026-03-012026-08-23
Mix3190d
- Insider21(68%)
- SEC Filings6(19%)
- Other2(6%)
- Offering1(3%)
- Leadership1(3%)
Latest news
25 items- INSIDERChief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 3 filed by new insider Edwards Larry Todd3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECOruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PROruka Therapeutics Appoints Todd Edwards as Chief Commercial OfficerMENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026. Mr. Edwards brings more than 25 years of commercial leadership experience across immunology and dermatology, spanning both biologics and topical therapies. He joins Oruka from Arcutis Biotherapeutics, Inc., where he served as Executive Vice President and Chief Commercial Officer a
- SECSEC Form S-3 filed by Oruka Therapeutics Inc.S-3 - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERChief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERGeneral Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECSEC Form 10-Q filed by Oruka Therapeutics Inc.10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PROruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateEVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026Phase 3 program for ORKA-001 expected to begin in 1H 2027ORCA-SURGE Week 16 data accelerated, now expected in 1Q 2027ORCA-SPLASH, a Phase 2 trial of ORKA-002 in moderate-to-severe hidradenitis suppurativa, initiated ORKA-004, a novel half-life extended monoclonal antibody targeting TL1A, to enter the clinic in 4Q 2026 Cash, cash equivalents and marketable securities of $1.1 billion expected to fund the Company through a BLA filing for ORKA-001 MENLO PARK, Calif., Aug. 10, 2026 (GLOBE NEWSWIR
- SECOruka Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERChief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERDirector Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERGeneral Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERDirector Dambkowski Carl sold $2,454,382 worth of shares (35,000 units at $70.13) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 38,743 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECOruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERSEC Form 4 filed by Director Dambkowski Carl4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 4 filed by Director Kulkarni Samarth4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
ORKA FAQ
5 questionsWhere does ORKA stock trade?
Oruka Therapeutics Inc. (ORKA) is listed on NASDAQ.What sector and industry is ORKA in?
Oruka Therapeutics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about ORKA?
Oruka Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight on 2025-12-18. Recent price targets range from $2000.00 to $4900.00.What companies are similar to ORKA?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.), NEOG (Neogen Corporation). Compare ORKA side-by-side with any of them on Quantisnow.How can I track ORKA on Quantisnow?
Quantisnow aggregates Oruka Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORKA to receive live email and push alerts on every new disclosure.